Lipocine Q3 2024 Earnings Results & Report

Lipocine EPS Results

• Actual EPS: -$0.44
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 8 quarters

Lipocine Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lipocine (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of poorly bioavailable compounds, with the goal of offering alternatives to injectable or otherwise inconvenient treatments.

Lipocine’s development programs have included oral hormone-replacement therapies, treatments for central nervous system disorders, and therapies for metabolic and liver-related conditions. Its lead product, TLANDO (testosterone undecanoate), was approved by the U.S. Food and Drug Administration in 2022 as an oral testosterone-replacement therapy for adult males with conditions associated with a deficiency or absence of endogenous testosterone.

Based in Salt Lake City, Utah, Lipocine has historically focused primarily on the U.S. pharmaceutical market while advancing its pipeline through clinical development and commercial partnerships. The company is led by Mahesh Karande, who has served as its president and chief executive officer. Lipocine continues to evaluate and develop additional candidates based on its oral drug-delivery platform.